tbuckley/cabot-search huggingface dataset:
Contents
Authors: Arundhati Anshu, Anand Parthasarathy, Jodhbir Mehta, Hla Htoon, Donald Tan, Soon-Phaik Chee, Mark Terry, Neda Shamie, Edwin Chen, Paul Phillips, Anand Shah, Karen Hoar, Daniel Friend, Anthony Aldave, Khairidzan Kamal, Rosalind Vo, Fei Yu, Jin Jie, Elena Rochtchina, Ava Tan, Robert Cumming, Stephen Leeder, Paul Mitchell, Kristiana Neff, Helga Sandoval, Luis Ferna ´ndez De Castro, Amy Nowacki, David Vroman, Kerry Solomon, Don Davis, Jacob Brubaker, Ladan Espandar, Jack Stringham, Alan Crandall, Liliana Werner, Nick Mamalis, H Dick, Camille Budo, Francois Malecaze, Josep Gu ¨ell, Antonio Marinho, Rudy Nuijts, Gregorius Luyten, Jose Menezo, Thomas Kohnen, Elizabeth Niemiec, Kent Anderson, Ingrid Scott, Paul Greenberg, Chie Sotozono, Mayumi Ueta, Noriko Koizumi, Tsutomu Inatomi, Yuji Shirakata, Zenro Ikezawa, Koji Hashimoto, Shigeru Kinoshita, Joseph Biber, Brian Groat, Michelle Ying, John French, Eric Donnenfeld, Richard Lindstrom, Steve Schallhorn, David Tanzer, Sandor Kaupp, Mitch Brown, Stephanie Malady, Anjali Bhorade, Mae Gordon, Brad Wilson, Robert Weinrab, Michael Kass, Clement Tham, Yolanda Kwong, Dexter Leung, S Lam, Felix Li, Thomas Chiu, Jonathan Chan, Dennis Lam, Jimmy Lai
Journal: Ophthalmology (2009)
Century Plants
Authors: G. G. Smith
Journal: New England Journal of Medicine (1957)

ACCORDING to Kipling: "Anything green that grew out of the mould Was an excellent herb to our fathers of old." It is a couplet the truth of which is well illustrated by Garrison's History of Medicine; the earlier the reference, the more applicable the quotation. Thus, even "moss from the skull of a person who had died a violent death" was supposed at one time to have great curative powers, along with the king's touch and Irish whisky.Scientific observation was also emerging from time to time in matters not directly related to the product of the Irish stills; . . .
Presence of Lactulose in Urine of Infants With Lactosuria
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Attitudes toward clinical trials among patients and the public
Authors: B. R. Cassileth
Journal: JAMA (1982)

Attitudes toward clinical research, the focus of recent and damaging media attention, were assessed through questionnaires completed anonymously by 104 patients with cancer, 84 cardiology patients, and 107 members of the general public. Responses differed neither by subgroup nor by demographic variables. Data are therefore reported on the total population of 295 subjects. Most respondents (71%) believed that patients should serve as research subjects. In support of this belief, the majority cited potential benefit to others and the opportunity to increase scientific knowledge, but a different bias emerged when they were asked about their own potential participation. This study shows that diverse respondents view clinical trials as important, ethical, and as a means of attaining superior clinical care. Major importance is attributed to making contributions to medical knowledge and to helping future patients. Contrasts are noted in patients' views of their own treatments<i>v</i>treatments of "hypothetical others." (<i>JAMA</i>1982;248:968-970)
Seeding the World With Stem Cells
Authors: B. Vastag
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survivin-specific T cell receptor targets tumor but not T cells
Authors: Caroline Arber, Xiang Feng, Harshal Abhyankar, Errika Romero, Meng-Fen Wu, Helen E. Heslop, Patrick Barth, Gianpietro Dotti, Barbara Savoldo
Journal: Journal of Clinical Investigation (2014)

Survivin is a tumor-associated antigen (TAA) that inhibits apoptosis and is widely overexpressed in cancer cells; therefore, survivin has potential as a target for cancer immunotherapy. Application of HLA-A2-restricted survivin-specific T cell receptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impeded by the inability of these TCRs to distinguish healthy cells expressing low levels of survivin from cancer cells with high survivin expression levels. Here, we identified an HLA-A2-restricted survivin-specific TCR isolated from autologous TCR repertoires that targets tumor cells in vitro and in vivo but does not cause fratricidal toxicity. Molecular modeling of the TCR-peptide-HLA ternary complexes and alanine scanning revealed that the autologously derived TCRs had tighter interactions with the survivin peptide than did fratricidal TCRs. Similar recognition patterns were observed among 7 additional TAA-specific TCRs isolated from allogeneic versus autologous repertoires. Together, the results from this study indicate that maximal peptide recognition is key for TCR selectivity and likely critical for reducing unwanted off-target toxicities. Moreover, isolating TCRs from autologous repertoires to maximize TCR selectivity has potential as a useful strategy to identify and select other shared tumor- and self-antigen-specific TCRs and ensure selective antitumor activity.
Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through 1992
Authors: C. H. Pui
Journal: JAMA (1995)

<h3>Objective.</h3> —To determine whether there is a racial difference in prognosis among childhood cancers. <h3>Design.</h3> —An overall (30-year) survival analysis by race was followed by separate studies for "early" and "recent" treatment eras, defined by time points at which significantly improved outcome was demonstrated for specific tumor types. Stratified analyses were performed to adjust for recognized prognostic features. <h3>Setting.</h3> —Pediatric oncology research and treatment center. <h3>Patients.</h3> —The study included 798 black and 4507 white children with newly diagnosed malignancies treated from January 1962 through June 1992. These patients were accepted for treatment regardless of their financial status and were enrolled on disease-specific protocols. <h3>Results.</h3> —Across the 30-year study period, black children had a significantly poorer rate of survival than white children (<i>P</i>&lt;.001, log-rank test). In the early treatment era, a significant difference was seen for all forms of cancer combined (<i>P</i>&lt;.001), with 10-year Kaplan-Meier estimates (±SE) of 37%±3% for black children and 50%±1% for white children. This difference largely reflected the poorer prognosis of black children with the most common childhood cancer, acute lymphoblastic leukemia. In the recent treatment era, there were no significant differences in treatment outcome by race for specific disease categories or for all forms of cancer combined. Ten-year survival rates were 67±6% for black children and 66%±3% for white children, indicating a significantly greater improvement in the former group. <h3>Conclusion.</h3> —With equal access to effective contemporary treatment, black children with cancer fare as well as white children when treated with protocol-based therapy at a pediatric oncology research center. (<i>JAMA</i>. 1995;273:633-637)
Clinical Lectures Delivered at the Metropolitan Free Hospital
Authors: B. Lucas
Journal: BMJ (1843)

tlle left; coughs a little; perspires a good deal in thc night.27. Has quite regained her color; has very little cough.Discharged, cured of the anTemia; phthisical symptoms relieved.CLINICAL REMARKS.Diagnosis.-This patient on her admission pre- sented all the usual symptoms of anemia.As the
Gynécologie opératoire.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VALUE OF VITAL STATISTICS TO MEDICAL SCIENCE
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hereditary spherocytosis with normal osmotic fragility after incubation. Is the autohemolysis test really obsolete?
Authors: N. Fukagawa
Journal: JAMA (1979)

Two patients in two families had hereditary spherocytosis but lacked a population of RBCs with increased osmotic fragility after incubation. The diagnosis in each patient was confirmed by the presence of splenomegaly, spherocytosis, reticulocytosis, and abnormal autohemolysis corrected by glucose. Sodium flux studies showed increased sodium permeability of the RBC membrane in one patient and normal permeability in another. Hereditary spherocytosis was also present in three other family members of patient 2. The autohemolysis test is of value in confirming the diagnosis in patients with hereditary spherocytosis and normal incubated osmotic fragility. (<i>JAMA</i>242:63-64, 1979)
Hepatology Highlights
Authors: Jean‐François Dufour
Journal: Hepatology (2016)

In Search of CheckpointImmune checkpoints favor T-cell exhaustion, which prevents immune rejection of tumor cells.Immune checkpoint inhibitors dramatically changed the prognosis of patients affected by cancers difficult to treat with conventional chemotherapies, such as melanoma.Checkpoint inhibitors are currently being tested for the treatment of hepatocellular carcinoma (HCC).Calderaro et al. performed a timely analysis of expression of the checkpoint, programmed death ligand 1 (PD-L1), in 217 HCCs.They found that expression of PD-L1 in neoplastic cells occurs in 17% of HCCs and is associated with features of tumor aggressiveness, whereas expression of PD-L1 in inflammatory cells occurs in 76% of HCCs and is associated with only some of these features.We will know in the near future if these tumors best respond to inhibitors of the PD-L1 pathway.(
Annals of Allergy, St. Paul
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mast cell chymase degrades fibrinogen and fibrin
Authors: T. Lipitsä, H. Siiskonen, A. Naukkarinen, I.T. Harvima
Journal: British Journal of Dermatology (2019)

Skin immune complex vasculitis is a relatively uncommon inflammatory condition which affects small blood vessels of the skin, causing damage in vessel walls. It causes purpura, which are purple spots on the skin that do not go pale on applying pressure. The spots are caused by bleeding underneath the skin. They are sometimes accompanied by skin necrosis (tissue death). Fibrin is a substance involved in blood clotting, and deposits of fibrin are found on vessel walls in vasculitis. When tissue damage results in bleeding, fibrinogen ‐ a protein that is produced by the liver and found in blood plasma ‐ is converted at the wound into fibrin by the action of an enzyme. A type of cells called mast cells are involved in the development of skin vasculitis. These cells contain heparin, which is an anticoagulant, meaning it helps stop blood clots forming. Mast cells also contain powerful enzymes, including chymase, that can affect blood coagulation (clotting) and degrade a variety of skin structures. Therefore, the researchers of this study employed by the Kuopio University Hospital and the University of Eastern Finland, investigated the role of chymase in blood coagulation and fibrinolysis, which is the process by which enzymes break down the fibrin in blood clots. A particular target was fibrinogen, as this blood protein is crucial in the formation of fibrin‐containing blood clots. The researchers found that chymase‐containing mast cells are in intimate contact with fibrin‐containing blood vessels in vasculitis. The treatment of vasculitis specimens with a version of chymase called ‘recombinant human (rh)‐chymase’ led to the disappearance of fibrin from vessel walls, an effect which was enhanced by heparin. In further experiments, it was found that rh‐chymase can degrade (break down) certain chains of fibrinogen and the degradation is regulated by heparin. Consequently, after treating fibrinogen with rh‐chymase, the clotting time of fibrinogen solution was markedly prolonged. The authors conclude that mast cell chymase may help clear fibrin from vessel walls in vasculitis.
Employment of MEDEX graduates and trainees. Five-year progress report for the United States
Authors: D. Lawrence
Journal: JAMA (1975)

The MEDEX approach to the training and deployment of physician extenders is described and contrasted with other physician-extender training models, and results of a survey of 277 MEDEX graduates and 207 trainees are presented. Practically all MEDEX graduates and trainees are employed in full-time practice and are working with fee-for-service family physicians in the rural areas of the United States, which suggests that the strategy used to place Medex practitioners into communities requiring additional health services has been successful. (<i>JAMA</i>234:174-177, 1975)
Grundzüge der pathologischen Physiologie
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meckel's Diverticulum: a Systematic Review
Authors: Jayesh Sagar, Vikas Kumar, D K Shah
Journal: Journal of the Royal Society of Medicine (2006)

Meckel's diverticulum is the most common congenital malformation of gastrointestinal tract. It can cause complications in the form of ulceration, haemorrhage, intussusception, intestinal obstruction, perforation and, very rarely, vesicodiverticular fistulae and tumours. These complications, especially bleeding, are more common in the paediatric age group than in adults; however it is not uncommon to miss the diagnosis of Meckel's diverticulum in adults. Here, we reviewed the literature regarding the complications of this forgotten clinical entity in adults with potential diagnostic difficulties and management strategies.
P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Authors: N. Liang, P. Xing, Y. Su, X. Long, Y. Gao, P. Chen, Z. Zhang, J. Liu, B. Li, T. Zhang, X. Mao, L. Zhang, H. Liu
Journal: Journal of Thoracic Oncology (2018)
THE CHEMISTRY OF THE PROTEID MOLECULE.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of care before and after implementation of the DRG-based prospective payment system. A summary of effects
Authors: W. H. Rogers
Journal: JAMA (1990)

In this series we have described changes in the quality of care that have occurred in the treatment of hospitalized elderly Medicare patients with one of five conditions between 1981-1982 and 1985-1986. In this article we report on a mortality analysis, patient and hospital subgroup comparisons, and time series studies we have conducted in an attempt to determine whether changes in quality of care can be linked causally to the introduction of the prospective payment system. Based on these analyses we conclude that (1) mortality following hospitalization has been unaffected by the introduction of the prospective payment system, and improvements in in-hospital processes of care that began prior to the prospective payment system have continued after its introduction, but (2) the prospective payment system has increased the likelihood that a patient will be discharged home in an unstable condition. We recommend that efforts to correct this problem be intensified and that clinical monitoring of the impact of the prospective payment system continue as hospital cost-containment pressures intensify. (<i>JAMA</i>. 1990;264:1989-1994)